Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
6 hedge funds and large institutions have $1.48K invested in Protagenic Therapeutics Warrant in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 3 → 6 (+3)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.73% more ownership
Funds ownership: 5.57% → 6.3% (+0.73%)
46% less capital invested
Capital invested by funds: $2.76K → $1.48K (-$1.28K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$198 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$183 |
| 3 |
TSS
Two Sigma Securities
New York
|
+$156 |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3 |
| 5 |
GS
GTS Securities
New York
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$62 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $1.04K | -$62 | -6,954 | -4% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $302 | +$183 | +20,558 | +44% |
|
|
GS
3
GTS Securities
New York
| $76 | +$1 | +100 | +0.4% |
|
|
TSS
4
Two Sigma Securities
New York
| $61 | +$156 | +17,500 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $1 | +$3 | +360 | New |
|
|
HF
6
HRT Financial
New York
| – | +$198 | +22,269 | New |
|
PTIXW Hedge Fund Activity: Q4 2024 in Review
6 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q4 2024, worth a combined $1.48K — down 46% from $2.76K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PTIXW positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $198. The largest seller was Warberg Asset Management, cutting an estimated $62.
- 6 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q4 2024, up from 3 in Q3 2024.
- Funds reported $1.48K of Protagenic Therapeutics Warrant stock for Q4 2024, down 46% quarter-over-quarter.
- 3 funds opened new Protagenic Therapeutics Warrant positions in Q4 2024 and 0 closed out, a net change of +3 holders.
- The largest Protagenic Therapeutics Warrant buyer in Q4 2024 was HRT Financial, an estimated $198 added.
- The largest Protagenic Therapeutics Warrant seller in Q4 2024 was Warberg Asset Management, an estimated $62 sold.
Based on aggregated 13F filings for Q4 2024.